OVERVIEW

Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care With Dr. David Smith is organized by National Association for Continuing Education (NACE).

Start Date: May 15, 2019
Expiration Date: May 14, 2020

Target Audience: Primary Care Providers

Credit(s):
• 1.0 AMA PRA Category 1 Credit™
• 1.0 AANP Contact Hour which includes 0.75 pharmacology hours

Estimated Time To Complete CME Activity: 1.0 hours

Summary:
Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. This activity will examine the current guidelines and recommendations for management of hyperlipidemia in high risk patients.

This webcast was recorded live at the Conversations in Primary Care 2019 and is being used with the permission of the presenters.

Learning Objectives:
After completing this program participants should be able to:
• Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes
• Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients
• Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk
• Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them

Additional details will be posted as soon as information is available.